Paper26323609
PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK and 17 others. Neuro Oncol, 2016. Cited by 500 papers, by iCite.
Cite this record
ConductScience Library. PD-L1 expression and prognostic impact in glioblastoma. Papers, record 26323609. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26323609
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| B7-H1 Antigen | Major topic |
| Biomarkers, Tumor | Major topic |
| Brain Neoplasms | Major topic |
| Glioblastoma | Major topic |
| T-Lymphocytes | Major topic |
| Adult | |
| Aged | |
| Animals | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Female | |
| Flow Cytometry | |
| Follow-Up Studies | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Immunoenzyme Techniques | |
| Male | |
| Mice | |
| Middle Aged | |
| Neoplasm Staging | |
| Prognosis | |
| RNA, Messenger | |
| Survival Rate |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA120813 | NCI NIH HHS | United States | R01CA120813 | PubMed and NIH | NIH RePORTER |
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| P50 CA093459 | NCI NIH HHS | United States | P50CA093459 | PubMed and NIH | NIH RePORTER |
| CA1208113 | NCI NIH HHS | United States | PubMed | PubMed | |
| P50 CA127001 | NCI NIH HHS | United States | P50CA127001 | PubMed and NIH | NIH RePORTER |
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25355681 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/25355681 | PubMed |
| 2 | 25193987 | PD-L1 expression in nonclear-cell renal cell carcinoma. | Ann Oncol | 2014 | https://conductscience.org/library/papers/25193987 | PubMed |
| 3 | 22290259 | Immunotherapy for the treatment of glioblastoma. | Cancer J | 2012 | https://conductscience.org/library/papers/22290259 | PubMed |
| 4 | 19202065 | B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19202065 | PubMed |
| 5 | 25034862 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. | Lancet | 2014 | https://conductscience.org/library/papers/25034862 | PubMed |
| 6 | 17629517 | Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. | Immunity | 2007 | https://conductscience.org/library/papers/17629517 | PubMed |
| 7 | 23986257 | PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. | J Neurosci | 2013 | https://conductscience.org/library/papers/23986257 | PubMed |
| 8 | 20667896 | Glioma cancer stem cells induce immunosuppressive macrophages/microglia. | Neuro Oncol | 2010 | https://conductscience.org/library/papers/20667896 | PubMed |
| 9 | 16723631 | An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. | Neuro Oncol | 2006 | https://conductscience.org/library/papers/16723631 | PubMed |
| 10 | 24409449 | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. | Cancer Immunol Res | 2013 | https://conductscience.org/library/papers/24409449 | PubMed |
| 11 | 23833564 | Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. | Cancer Immun | 2013 | https://conductscience.org/library/papers/23833564 | PubMed |
| 12 | 23977046 | Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. | PLoS One | 2013 | https://conductscience.org/library/papers/23977046 | PubMed |
| 13 | 25635347 | A new initiative on precision medicine. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25635347 | PubMed |
| 14 | 22441249 | PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia. | AIDS | 2012 | https://conductscience.org/library/papers/22441249 | PubMed |
| 15 | 24691018 | Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24691018 | PubMed |
| 16 | 17159987 | Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. | Nat Med | 2007 | https://conductscience.org/library/papers/17159987 | PubMed |
| 17 | 25586468 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/25586468 | PubMed |
| 18 | 25594174 | Molecular and genetic properties of tumors associated with local immune cytolytic activity. | Cell | 2015 | https://conductscience.org/library/papers/25594174 | PubMed |
| 19 | 18585785 | Interaction of human PD-L1 and B7-1. | Mol Immunol | 2008 | https://conductscience.org/library/papers/18585785 | PubMed |
| 20 | 23724846 | Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23724846 | PubMed |
Cited by398
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 500 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42965172 | Corticosteroid treatment modulates immune cell populations in the glioblastoma microenvironment. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42965172 | PubMed |
| 42958266 | MRgFUS-enabled nanogel platform for synergstic chemo-immunotherapy in glioblastoma. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42958266 | PubMed |
| 42699700 | Newcastle Disease Virus - Induced Interferons Regulate PD-L1 and MICA Expression in Human Tumor and Normal Cells. | Immunotargets Ther | 2026 | https://conductscience.org/library/papers/42699700 | PubMed |
| 42652167 | EFEMP2 Is Associated with Shelterin-Related DNA Damage Repair, Immune Microenvironment Features, and Prognosis in Glioblastoma. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652167 | PubMed |
| 42649887 | Fatty Acid Metabolism Rewires Glioblastoma Progression and Treg-Mediated Immune Resistance. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649887 | PubMed |
| 42549384 | Glioblastoma beyond the Brain: A Case Series Demonstrating Systemic Metastatic Potential. | Case Rep Oncol | 2026 | https://conductscience.org/library/papers/42549384 | PubMed |
| 42396877 | Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment. | Immunol Cell Biol | 2026 | https://conductscience.org/library/papers/42396877 | PubMed |
| 42101535 | Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42101535 | PubMed |
| 41995753 | Extracellular vesicles mediate intercellular transfer of PD-L1 and bystander T-cell suppression. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/41995753 | PubMed |
| 41909736 | Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/41909736 | PubMed |
| 41851421 | Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme. | Commun Med (Lond) | 2026 | https://conductscience.org/library/papers/41851421 | PubMed |
| 41689429 | The Application of PD-1 Inhibitors in Immunotherapy for Glioblastoma. | FASEB J | 2026 | https://conductscience.org/library/papers/41689429 | PubMed |
| 41617829 | Reduced expression of BIRC2 and BIRC3 associated with longer survival in pediatric high-grade gliomas. | Sci Rep | 2026 | https://conductscience.org/library/papers/41617829 | PubMed |
| 41583467 | Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies. | Front Immunol | 2025 | https://conductscience.org/library/papers/41583467 | PubMed |
| 41579222 | From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas. | Cell Mol Neurobiol | 2026 | https://conductscience.org/library/papers/41579222 | PubMed |
| 41578162 | MRPS16 Regulates NFATC2 Through the Wnt/β-Catenin Pathway to Promote Glioma Proliferation. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/41578162 | PubMed |
| 41577996 | Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential. | Neurosurg Rev | 2026 | https://conductscience.org/library/papers/41577996 | PubMed |
| 41438616 | A Cuproptosis-Related lncRNA Signature Predicts Prognosis and Shapes the Immune Landscape in Primary Lower-Grade Glioma. | Genet Res (Camb) | 2025 | https://conductscience.org/library/papers/41438616 | PubMed |
| 41433099 | Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models. | J Clin Invest | 2026 | https://conductscience.org/library/papers/41433099 | PubMed |
| 41395274 | Study on the anti-tumor effect of PDL1-CAR-γδT cells constructed with nanobody sequences on glioblastoma. | Am J Cancer Res | 2025 | https://conductscience.org/library/papers/41395274 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| SPATA2 | 9825 | PubTator's text mining | https://conductscience.org/library/genes/9825 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26323609
GET https://conductscience.org/api/papers/v1/26323609/references?page=2